$BLLN

BillionToOne, Inc.

BillionToOne develops molecular diagnostic tests using a single-molecule next-generation sequencing platform to analyze cell-free DNA from blood samples. Its customers include prenatal and oncology clinicians, who use the tests to assess fetal genetic risks, guide cancer therapy selection and monitor treatment response. BillionToOne’s products include the UNITY prenatal testing portfolio, which screens for recessive conditions, aneuploidies and fetal antigens, and the Northstar oncology portfolio, comprising Northstar Select for therapy-selection insights and Northstar Response for tracking tumor burden and response to therapy. BillionToOne makes money by providing diagnostic testing services. Its tests use proprietary Quantitative Counting Templates and sequencing and analytical methods to quantify genetic signals in samples. The company also provides software tools supporting the testing workflow for patients and providers. BillionToOne is headquartered in Menlo Park, California.

AlphAI earnings readThird quarter 2026 · NOV 4BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
1
—
$7.1M
Atay Oguzhan
100%
See all $BLLN insider activity →
Low

billiontoone responds to short seller report

BillionToOne (BLLN) responded to a short seller report by Fuzzy Panda Research, which holds a short position in the company. BLLN called the report inaccurate and misleading, defending its practices and disclosures. The company is reviewing legal options. BLLN develops molecular diagnostic tests and is headquartered in California.

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

BLLN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BLLN (BillionToOne, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent BLLN coverage spans financial news, insider activity and market movers.

In the last 30 days, BLLN insiders filed 32 SEC Form 4 transactions — no purchases and 32 sales ($7.1M). The most active reporter was Atay Oguzhan, Chairman and CEO, with 16 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving BLLN

  • The company’s rebuttal to a short-seller report can shift near-term sentiment and trading flows, but the article provides no new financial or regulatory datapoints.

    investing.com · Nov 18, 2026

  • BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

    investing.com · Nov 18, 2026

  • Bearish overhang from fraud and reimbursement allegations, with potential downside if regulators or insurers escalate scrutiny.

    investing.com · Nov 18, 2026

  • Piper Sandler kept BillionToOne's rating at Overweight but reduced its price target from $140 to $130, a 7.1% drop. The new target suggests a 13.1% upside from the Nov 9 close of $114.95.

    tradingview.com · Nov 10, 2026

  • JP Morgan kept its Overweight rating on BillionToOne and increased its price target to $135 from $130, suggesting a 20.1% upside from the Nov 5 close of $112.39.

    tradingview.com · Nov 5, 2026

AlphAI scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BLLN

Score

billiontoone responds to short seller report

BillionToOne (BLLN) responded to a short seller report by Fuzzy Panda Research, which holds a short position in the company. BLLN called the report inaccurate and misleading, defending its practices and disclosures. The company is reviewing legal options. BLLN develops molecular diagnostic tests and is headquartered in California.

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

Billiontoone Q3 Earnings Call Highlights

BillionToOne (NASDAQ:BLLN) plans to launch Northstar Clear, a tissue-free MRD test, on Dec. 15. The test will be available for all solid tumors, with initial data focused on colorectal cancer. The company expects modest revenue from Clear in 2027. BillionToOne also highlighted clinical evidence for its Unity Fetal Risk Screen and Northstar Response tests. The company is targeting larger health systems for its prenatal products, with over 20 systems in the pipeline.

$BLLNHighAI 8/10Earnings

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,

Related tickers